

Datasheet for ABIN2667420 GDNF Protein (AA 78-211, N-Term)



Go to Product page

| Overview | |
|--------------------------|---|
| Quantity: | 10 µg |
| Target: | GDNF |
| Protein Characteristics: | N-Term, AA 78-211 |
| Origin: | Human |
| Source: | Escherichia coli (E. coli) |
| Protein Type: | Recombinant |
| Biological Activity: | Active |
| Application: | Flow Cytometry (FACS) |
| Product Details | |
| Purity: | >98 % , as determined by Coomassie stained SDS-PAGE. |
| Endotoxin Level: | Less than 0.1 ng per µg of protein. |
| Target Details | |
| Target: | GDNF |
| Alternative Name: | GDNF (GDNF Products) |
| Background: | Glial cell line-derived neurotrophic factor (GDNF) is a member of the TGF- β superfamily and |
| | was first identified as a growth factor supporting the survival of embryonic midbrain neurons. |
| | GDNF has been shown to promote the development, differentiation, and survival of |
| | dopaminergic neurons by signaling through GDNF family receptor α -1 (GFR α 1) and the |
| | coreceptor Ret receptor tyrosine kinase. Dysregulated expression of GDNF has been reported |

Order at www.antibodies-online.com | www.antikoerper-online.de | www.anticorps-enligne.fr | www.antibodies-online.cn International: +49 (0)241 95 163 153 | USA & Canada: +1 877 302 8632 | support@antibodies-online.com Page 1/2 | Product datasheet for ABIN2667420 | 07/26/2024 | Copyright antibodies-online. All rights reserved.

Target Details

| | to be associated with several mental diseases, including depression and schizophrenia. GDNF |
|---------------------|--|
| | is considered as a promising therapeutic agent for the treatment of Parkinson's disease, since |
| | GNDF can protect dopaminergic neurons from neurotoxin and promotes neuron regeneration |
| | after injury. In addition to the functions in the nervous system, GDNF is also required for the |
| | differentiation of spermatogonia and development of kidney. Upregulated expression of GNDF |
| | was observed in various cancer cell lines and correlates with malignant cancer progression, |
| | suggesting a role of GDNF in carcinogenesis. |
| Molecular Weight: | The 135 amino acid recombinant protein has a predicted molecular mass of approximately |
| | 15.0 kDa. Recombinant human GDNF forms a a disulfide-linked homodimer. The predicted N- |
| | terminal amino acid is Met. |
| Pathways: | RTK Signaling, Synaptic Membrane, Tube Formation, Autophagy, Smooth Muscle Cell Migration |
| | |
| Application Details | |
| Application Notes: | Optimal working dilution should be determined by the investigator. |
| Comment: | Biological activity: ED50 \leq 0.1 ng/ml, corresponding to a specific activity of \geq 1.0 x 107 units/mg, |
| | as measured by its ability to stimulate proliferation of rat C6 cells in a dose dependent manner. |
| Restrictions: | For Research Use only |
| Handling | |
| Format: | Lyophilized |
| Reconstitution: | For maximum results, quick spin vial prior to opening. Reconstitute in water to a concentration |
| | of 0.1-1.0 mg/mL. Do not vortex. It is recommended to further dilute in a buffer, such as 5 $\%$ |
| | Trehalose, and store in working aliquots at -20 °C to -80 °C. |
| Buffer: | Lyophilized, carrier-free. |
| Handling Advice: | Avoid repeated freeze/thaw cycles. |
| Storage: | -20 °C |
| Storage Comment: | Unopened vial can be stored at -20°C or -70°C. |
| | |